TherapeuticsMD to License its Products to Mayne Pharma

 TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments -

- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD’s products -

- Transaction allows TXMD to recapitalize and transform into a pharmaceutical royalty company -

https://finance.yahoo.com/news/therapeuticsmd-announces-definitive-agreements-license-230000161.html